Future Science Group
Browse
Supplementary Tables 1-4.docx (17.07 kB)
Download file

Supplementary Tables – Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis

Download (17.07 kB)
dataset
posted on 2022-02-07, 14:04 authored by Figshare Future Science GroupFigshare Future Science Group, Jiarui Chen, Xingyu Liu, Junhong Zhang, Zhao Huang, Wei Zeng, Jing Hu, Gang Chen, Yan Gong, Yu Liu, Conghua Xie

Supplementary Table S1–S4. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis

Funding

National Natural Science Foundation of China (81773236, 81800429 and 81972852)

Key Research & Development Project of Hubei Province (2020BCA069)

Nature Science Foundation of Hubei Province (2020CFB612)

Health Commission of Hubei Province Medical Leading Talent Project, Young and Middle-Aged Medical Backbone Talents of Wuhan (WHQG201902)

Application Foundation Frontier Project of Wuhan (2020020601012221)

Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (znpy2019001, znpy2019048, and ZNJC201922)

Chinese Society of Clinical Oncology Top Alliance Tumor Immune Research Fund (Y-JS2019-036)

History

Usage metrics

Read the peer-reviewed publication

Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small cell lung cancer: a network meta-analysis
Future OncologyFuture Oncology

Categories

Keywords

PD-1/PD-L1 inhibitorbevacizumabchemotherapynon-small cell lung cancercombined interventionsPD-L1 expressionliver metastasissurvivaladverse eventsnetwork meta-analysisCancer Cell BiologyCancer Therapy (excl. Chemotherapy and Radiation Therapy)ChemotherapyMolecular TargetsSolid Tumours

Licence

CC BY-NC-ND 4.0

Exports